Therapy for Argentine hemorrhagic fever in nonhuman primates with a humanized monoclonal antibody.

ABSTRACT: The COVID-19 pandemic has reemphasized the need to identify safe and scalable therapeutics to slow or reverse symptoms of disease caused by newly emerging and reemerging viral pathogens. Recent clinical successes of monoclonal antibodies (mAbs) in therapy for viral infections demonstrate that mAbs offer a solution for these emerging biothreats. We have explored this with respect to Junin virus (JUNV), an arenavirus classified as a category A high-priority agent and the causative agent of Argentine hemorrhagic fever (AHF). There are currently no Food and Drug Administration-approved drugs available for preventing or treating AHF, although immune plasma from convalescent patients is used routinely to treat active infections. However, immune plasma is severely limited in quantity, highly vari

SUBMITTER: Zeitlin L 

PROVIDER: S-EPMC7980402 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature